Autoria(s):
Jiménez-Navarro, Manuel; Molero, Encarnación; Teresa, Eduardo de
Data(s)
16/11/2015
16/11/2015
28/03/2002
Resumo
To the Editor:
The value of angiotensin-converting–
enzyme (ACE) inhibitors, beta-blockers, and spironolactone has been well established by the results of numerous clinical trials. About 70 percent of the patients described by Rose et al. were treated with ACE inhibitors or angiotensin II–receptor antagonists; 35 to 40 percent received spironolactone, and only about 20 percent received beta-blockers. Thus, this population cannot have been considered to be optimally treated from the point of view of medical therapy.
Identificador
Jiménez-Navarro M, Molero E, Teresa E de. Left ventricular assist device. N. Engl. J. Med.. 2002; 346(13):1023-5; author reply 1023-5
